SEC/Sec. 16 Filings

Form 10-K
ORASURE TECHNOLOGIES INC filed this Form 10-K on 02/28/2018
Document Outline
Entire Document (4248.3 KB)
Subdocument 1 - 10-K - 10-K
Page 1 - UNITED STATES
Page 2 - Table of Contents
Page 3 - This Report contains certain forward-looking statements, within the meaning of the Federal securitie
Page 4 - Accordingly, stockholders should not assume that we agree with any statement or report issued by any
Page 5 - PART I
Page 6 - Products
Page 7 - N/A
Page 8 - N/A
Page 9 - OraQuick Rapid HIV Test
Page 10 - OraQuick In-Home HIV Test
Page 11 - OraSure Collection Device
Page 12 - Intercept Drug Testing System
Page 13 - he
Page 14 - Western blot HIV-1 Confirmatory Test
Page 15 - Molecular Collections
Page 16 - Infectious Disease Testing - Professional
Page 17 - Molecular Collection Systems
Page 18 - Cryosurgical Systems
Page 19 - Significant Products and Customers
Page 20 - Employees
Page 21 - N/A
Page 22 - N/A
Page 23 - Patents and Proprietary Information
Page 24 - ADVANCE
Page 25 - Domestic Regulation
Page 26 - de novo
Page 27 - ADVANCE
Page 28 - Import and Export Requirements
Page 29 - ADVANCE
Page 30 - Foreign Corrupt Practices Act and Other Anti-Corruption Laws
Page 31 - You should carefully consider the risks and uncertainties described below, together with all of the
Page 32 - Failure to Comply With FDA or Other Regulatory Requirements May Require Us to Suspend Production or
Page 33 - Our Inability to Manufacture Products in Accordance With Applicable Specifications, Performance Stan
Page 34 - Compliance With Regulations Governing Public Company Corporate Governance and Reporting is Complex a
Page 35 - Federal and State Laws Pertaining to Healthcare Fraud and Abuse Could Adversely Affect Our Business,
Page 36 - Consolidation in the Healthcare Industry Could Adversely Affect Our Future Revenues and Operating Re
Page 37 - Failure to Successfully Commercialize Rapid Point of-Care Ebola and Zika Tests Could Adversely Affec
Page 38 - If We Do Not Successfully Manage the Transition Associated with the Appointment of a New Chief Execu
Page 39 - Our Revenues Could be Affected by Third-Party Reimbursement Policies and Potential Cost Constraints.
Page 40 - New or Changed Testing Guidelines Could Affect Sales of Our Diagnostic Products.
Page 41 - Developments Related To The U.K. s Referendum On Membership in The E.U. Could Adversely Affect Us.
Page 42 - We Rely on Information Technology in Our Operations and Any Material Failure, Inadequacy, Interrupti
Page 43 - Risks Relating to Collaborators
Page 44 - We May Need Strategic Partners to Assist in Developing and Commercializing Some of Our Products.
Page 45 - Risks Relating to Intellectual Property
Page 46 - We May Become Involved in Intellectual Property Disputes, Which Could Increase our Costs and Limit o
Page 47 - Risks Relating to Products, Marketing and Sales
Page 48 - Our Customers May Resist Adoption of Rapid Point-of-Care Diagnostic Testing.
Page 49 - Our Inability to Carry Out Certain of Our Marketing and Sales Plans May Make it Difficult for Us to
Page 50 - The Insurance We Purchase to Cover Our Potential Business Risks May be Inadequate.
Page 51 - Our International Presence May Increase Our Risks and Expose Our Business to Regulatory, Cultural or
Page 52 - Our U.S. Government Contracts Require Compliance With Numerous Laws and Increases Our Risk and Liabi
Page 53 - Our U.S. Government Contracts May Affect our Intellectual Property Rights.
Page 54 - Risks Relating to the Economy, Our Financial Results, Investments, Credit Facilities and Need for Fi
Page 55 - We May Experience Fluctuations in Our Financial Results or Fail to Meet Our Financial Projections.
Page 56 - Tax Matters, Including the Changes in Corporate Tax Rates, Disagreements with Taxing Authorities and
Page 57 - We May Require Future Additional Capital.
Page 58 - Future Sales of Our Common Stock by Existing Stockholders, Executive Officers or Directors Could Dep
Page 59 - Investor Confidence and Share Value May be Adversely Impacted if We and/or Our Independent Registere
Page 60 - Future Sales of Shares of Our Common Stock Could Adversely Affect the Trading Price of Our Common St
Page 61 - PART II
Page 62 - Performance Graph
Page 63 - Securities Authorized for Issuance Under Equity Compensation Plans
Page 64 - Statements below regarding future events or performance are forward-looking statements within the me
Page 65 - Gates Foundation
Page 66 - Current Consolidated Financial Results
Page 67 - Net Revenues by Segment
Page 68 - Risk Assessment Market
Page 69 - Other revenues
Page 70 - CONSOLIDATED OPERATING RESULTS
Page 71 - CONSOLIDATED INCOME TAXES
Page 72 - Net Revenues by Segment
Page 73 - Risk Assessment Market
Page 74 - Other revenues
Page 75 - OPERATING INCOME BY SEGMENT
Page 76 - Liquidity and Capital Resources
Page 77 - Contractual Obligations and Commercial Commitments
Page 78 - Revenue Recognition
Page 79 - Inventories
Page 80 - N/A
Page 81 - Evaluation of Disclosure Controls and Procedures
Page 82 - Internal Control Integrated Framework
Page 83 - PART III
Page 84 - PART IV
Page 85 - N/A
Page 86 - Index to Consolidated Financial Statements
Page 87 - REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
Page 88 - ORASURE TECHNOLOGIES, INC. AND SUBSIDIARIES
Page 89 - ORASURE TECHNOLOGIES, INC. AND SUBSIDIARIES
Page 90 - ORASURE TECHNOLOGIES, INC. AND SUBSIDIARIES
Page 91 - ORASURE TECHNOLOGIES, INC. AND SUBSIDIARIES
Page 92 - ORASURE TECHNOLOGIES, INC. AND SUBSIDIARIES
Page 93 - ORASURE TECHNOLOGIES, INC. AND SUBSIDIARIES
Page 94 - Supplemental Cash Flow Information
Page 95 - Property and Equipment
Page 96 - Customer Sales Returns and Allowances
Page 97 - Deferred Revenue
Page 98 - Foreign Currency Translation
Page 99 - Accumulated Other Comprehensive Loss
Page 100 - Recent Accounting Pronouncements
Page 101 - Compensation-Stock Compensation (Topic 718) Improvements to Employee Share-Based Payment Accounting
Page 102 - N/A
Page 103 - N/A
Page 104 - The Tax Cuts and Jobs Act
Page 105 - N/A
Page 106 - N/A
Page 107 - Stock-Based Awards
Page 108 - N/A
Page 109 - N/A
Page 110 - N/A
Page 111 - Share Repurchase Program
Page 112 - N/A
Page 113 - Sublicense Agreement
Page 114 - Standby Letters of Credit
Page 115 - N/A
Page 116 - N/A
Page 117 - INDEX TO EXHIBITS
Page 118 - N/A
Page 119 - N/A
Page 120 - N/A
Subdocument 2 - EX-3.2 - EX-3.2
Page 1 - Exhibit 3.2
Page 2 - SECTION 3. Lost or Destroyed Stock Certificates.
Page 3 - SECTION 2. Special Meeting.
Page 4 - SECTION 5. Presentation of Business at Stockholders Meetings.
Page 5 - N/A
Page 6 - SECTION 6. Presiding Officials.
Page 7 - SECTION 2. Qualification and Election of Directors.
Page 8 - SECTION 5. Notice; Telephonic Attendance; Unanimous Consent.
Page 9 - SECTION 9. Compensation; Reimbursement of Expenses.
Page 10 - N/A
Page 11 - SECTION 11. Committees.
Page 12 - ARTICLE V
Page 13 - SECTION 4. President.
Page 14 - SECTION 6. Secretary and Assistant Secretaries.
Page 15 - ARTICLE VIII
Subdocument 3 - EX-23 - EX-23
Page 1 - Exhibit 23
Subdocument 4 - EX-24 - EX-24
Page 1 - Exhibit 24
Page 2 - POWER OF ATTORNEY
Page 3 - POWER OF ATTORNEY
Page 4 - POWER OF ATTORNEY
Page 5 - POWER OF ATTORNEY
Page 6 - POWER OF ATTORNEY
Page 7 - POWER OF ATTORNEY
Page 8 - POWER OF ATTORNEY
Page 9 - POWER OF ATTORNEY
Subdocument 5 - EX-31.1 - EX-31.1
Page 1 - Exhibit 31.1
Subdocument 6 - EX-31.2 - EX-31.2
Page 1 - Exhibit 31.2
Subdocument 7 - EX-32.1 - EX-32.1
Page 1 - Exhibit 32.1
Subdocument 8 - EX-32.2 - EX-32.2
Page 1 - Exhibit 32.2
XBRL Item - EX-101.INS - XBRL INSTANCE DOCUMENT (What's this?)
XBRL Item - EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA (What's this?)
XBRL Item - EX-101.CAL - XBRL TAXONOMY EXTENSION CALCULATION LINKBASE (What's this?)
XBRL Item - EX-101.DEF - XBRL TAXONOMY EXTENSION DEFINITION LINKBASE (What's this?)
XBRL Item - EX-101.LAB - XBRL TAXONOMY EXTENSION LABEL LINKBASE (What's this?)
XBRL Item - EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE (What's this?)
XBRL Viewer



Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts | IR Contacts IR Contacts | Financial Tear Sheet Financial Tear Sheet